Phase I dose escalation studies in Oncology: a call for on-study safety and flexibility Bill Mietlowski, Biometrics and Data Management, Novartis Oncology.
1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.
Analysis of Clinical Trials with Multiple Outcomes Changchun Xie, PhD Assistant Professor of Biostatistics Division of Biostatistics and Bioinformatics.
